Revenue surged to $51.0 million in 2026Q1, though persistent operating inefficiencies resulted in a negative operating margin of -39.8%.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Sales/Revenue | 140.49M | 109.79M | 90.4M | 82.71M | 64.36M | 48.04M | 11.8M | 18K | 1.13M | 8.16M | 17.53M | 0 | 0 | 0 |
| Revenue Growth % | 52.92% | 21.45% | 9.29% | 28.52% | 33.96% | 307.17% | 65450% | -98.4% | -86.17% | -53.46% | - | - | - | - |
| Cost of Goods Sold | 14.26M | 12.45M | 8.88M | 9.36M | 7.65M | 5.16M | 1.01M | 0 | 1.8M | 600K | 28K | 113K | 0 | 0 |
| COGS % of Revenue | - | 11.34% | 9.82% | 11.32% | 11.89% | 10.73% | 8.55% | - | 159.84% | 7.35% | 0.16% | - | - | - |
| Gross Profit | 126.24M | 97.34M | 81.52M | 73.35M | 56.7M | 42.88M | 10.79M | 18K | -675K | 7.56M | 17.5M | -113K | 0 | 0 |
| Gross Margin % | 89.85% | 88.66% | 90.18% | 88.68% | 88.11% | 89.27% | 91.45% | 100% | -59.84% | 92.65% | 99.84% | - | - | - |
| Gross Profit Growth % | - | 19.41% | 11.13% | 29.36% | 32.22% | 297.45% | 59844.44% | 102.67% | -108.93% | -56.82% | 15588.5% | - | - | - |
| Operating Expenses | 234.45M | 222.2M | 178.3M | 138.89M | 135.74M | 135.18M | 137.53M | 109.5M | 76.5M | 27.51M | 16.7M | 12.41M | 4.36M | 3.39M |
| OpEx % of Revenue | - | 202.39% | 197.24% | 167.92% | 210.92% | 281.37% | 1165.6% | 608311.11% | 6782.36% | 337.19% | 95.29% | - | - | - |
| Selling, General & Admin | 171.62M | 155.1M | 0 | 93.27M | 82.84M | 0 | 90.22M | 60.2M | 39.57M | 8.81M | 6.42M | 1.9M | 890K | 1.05M |
| SG&A % of Revenue | - | 141.27% | - | 112.77% | 128.72% | - | 764.63% | 334438.89% | 3508.07% | 108% | 36.61% | - | - | - |
| Research & Development | 62.83M | 67.11M | 57.15M | 45.61M | 52.91M | 47.64M | 47.31M | 49.3M | 36.93M | 18.7M | 10.29M | 10.52M | 4.01M | 2.33M |
| R&D % of Revenue | - | 61.12% | 63.21% | 55.15% | 82.21% | 99.17% | 400.97% | 273872.22% | 3274.29% | 229.19% | 58.68% | - | - | - |
| Other Operating Expenses | 0 | 0 | 121.15M | 0 | 0 | 87.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -108.21M | -124.86M | -96.78M | -65.54M | -79.04M | -92.29M | -126.74M | -109.48M | -77.18M | -19.95M | 798K | -12.41M | -4.37M | -3.39M |
| Operating Margin % | -77.02% | -113.73% | -107.06% | -79.23% | -122.82% | -192.11% | -1074.15% | -608211.11% | -6842.2% | -244.55% | 4.55% | - | - | - |
| Operating Income Growth % | - | -29.01% | -47.68% | 17.09% | 14.36% | 27.18% | -15.77% | -41.85% | -286.87% | -2600% | 106.43% | -184.05% | -28.92% | - |
| EBITDA | -105.65M | -122.45M | -96.45M | -63.83M | -77.22M | -91.46M | -124.69M | -108.15M | -76.76M | -19.74M | 1.01M | -12.3M | -4.34M | -3.37M |
| EBITDA Margin % | -75.2% | -111.54% | -106.7% | -77.17% | -119.99% | -190.38% | -1056.83% | -600855.56% | -6805.23% | -242.01% | 5.77% | - | - | - |
| EBITDA Growth % | 1.14% | -26.96% | -51.11% | 17.34% | 15.57% | 26.65% | -15.29% | -40.89% | -288.81% | -2052.82% | 108.22% | -183.41% | -28.72% | - |
| D&A (Non-Cash Add-back) | 2.57M | 2.41M | 329K | 1.71M | 1.82M | 831K | 2.04M | 1.32M | 417K | 207K | 213K | 113K | 30K | 18K |
| EBIT | -118.95M | -138.07M | -95.68M | -62.06M | -78.03M | -92.29M | -124.75M | -109.48M | -77.18M | -19.95M | 798K | -12.41M | -4.37M | -3.39M |
| Net Interest Income | -33.78M | -27.88M | -3.62M | -12.07M | -7.5M | 365K | 1.63M | 4.33M | 1.87M | 125K | 1K | 0 | 0 | 0 |
| Interest Income | 4.69M | 5.96M | 8.9M | 2.64M | 938K | 365K | 1.99M | 4.62M | 1.87M | 125K | 1K | 0 | 120K | 83K |
| Interest Expense | 38.47M | 33.85M | 12.52M | 14.71M | 8.44M | 0 | 357K | 284K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -30.1M | -28.55M | -27.26M | -32.79M | -28.99M | -17.08M | 1.63M | 4.33M | 1.65M | -31K | -2.74M | -279K | -107K | 83K |
| Pretax Income | -138.31M | -153.42M | -124.04M | -98.32M | -108.03M | -109.37M | -125.11M | -105.15M | -75.53M | -19.98M | -1.94M | -12.69M | -4.48M | -3.31M |
| Pretax Margin % | -98.45% | -139.74% | -137.22% | -118.87% | -167.86% | -227.66% | -1060.34% | -584144.44% | -6696.1% | -244.93% | -11.07% | - | - | - |
| Income Tax | -5.09M | 78K | 2.83M | 3.92M | 1.75M | 1.45M | 3.37M | 0 | 125K | 19K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 3.68% | -0.05% | -2.28% | -3.99% | -1.62% | -1.32% | -2.7% | 0% | -0.17% | -0.1% | 0% | 0% | 0% | 0% |
| Net Income | -133.22M | -153.49M | -126.87M | -102.24M | -109.78M | -110.82M | -128.48M | -105.15M | -75.66M | -20M | -1.94M | -12.69M | -4.56M | -3.31M |
| Net Margin % | -94.83% | -139.81% | -140.35% | -123.61% | -170.58% | -230.67% | -1088.94% | -584144.44% | -6707.18% | -245.16% | -11.07% | - | - | - |
| Net Income Growth % | 3.76% | -20.98% | -24.09% | 6.87% | 0.94% | 13.75% | -22.2% | -38.98% | -278.28% | -930.4% | 84.7% | -178.45% | -37.84% | - |
| Net Income (Continuing) | -133.22M | -153.49M | -126.87M | -102.24M | -109.78M | -110.82M | -128.48M | -105.15M | -75.66M | -20M | -1.94M | -12.69M | -4.48M | -3.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.65 | -3.19 | -2.96 | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 | -1.56 |
| EPS Growth % | 13.52% | -7.77% | 16.62% | 25.89% | 3.43% | 15.93% | -20.41% | -2.08% | -133.01% | -1187.5% | 97.1% | -178.28% | -26.92% | - |
| EPS (Basic) | - | -3.19 | -2.96 | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 | -1.56 |
| Diluted Shares Outstanding | 50.18M | 48.12M | 42.88M | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 11.97M | 2.3M | 2.3M | 2.12M |
| Basic Shares Outstanding | 50.18M | 48.12M | 42.88M | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 11.97M | 2.3M | 2.3M | 2.12M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Commercial adoption and liquidity
According to the most recent quarterly data, UroGen Pharma achieved a significant revenue acceleration to $51.0 million in 2026Q1, representing a 151.6% year-over-year growth rate, though investors should remain cautious regarding whether this spike reflects sustainable demand or temporary channel inventory fluctuations within the urology market.
The sharp revenue jump in the latest quarter suggests a potential inflection in Jelmyto adoption, yet the historical volatility in growth rates warrants skepticism. Analysts should monitor whether this trajectory is driven by genuine patient volume expansion or if it remains susceptible to the lumpy buy-and-bill cycles inherent in specialty urology practices.
As reported in financial statements, UroGen maintains robust gross margins consistently exceeding 88%, which suggests that the proprietary RTGel delivery platform commands significant pricing power despite the logistical challenges associated with cold-chain distribution and the specialized nature of the drug's administration in clinical settings.
The stability of these margins indicates that manufacturing and distribution costs are well-contained relative to the premium pricing of the therapy. This structural efficiency provides a strong foundation for profitability, provided the company can eventually scale its revenue base to cover the substantial fixed operating expenses currently weighing on the bottom line.
Based on reported figures, UroGen's operating expenses continue to outpace gross profit growth, resulting in a persistent negative operating margin that reached -39.8% in 2026Q1, indicating that the company has yet to achieve the necessary scale to leverage its heavy investment in commercial infrastructure and clinical research.
The lack of operating leverage suggests that every incremental dollar of revenue is currently being consumed by the high costs of maintaining a specialized sales force and ongoing R&D. Investors should monitor whether the anticipated UGN-102 launch can finally trigger a shift toward positive operating leverage or if the current cost structure is fundamentally misaligned with commercial reality.
While revenue growth appears promising, the market may be underestimating the procedural friction inherent in displacing traditional surgical standards like TURBT, as evidenced by the company's continued net losses and the significant capital requirements needed to sustain operations until a broader patient population is reached.
The reliance on urologists to fundamentally alter their practice workflow and economic incentives presents a significant barrier that simple drug efficacy data may not overcome. Short-term revenue gains may mask the difficulty of achieving widespread adoption, and the persistent cash burn suggests that the company remains highly vulnerable to capital market volatility.
Quick answers to the most common questions about buying URGN stock.
For fiscal year 2025, UroGen Pharma Ltd. (URGN) reported total revenue of $109.8M.
UroGen Pharma Ltd. (URGN) reported a net loss of $153.5M for the fiscal year ending 2025.
UroGen Pharma Ltd. (URGN) reported an operating income of $-124.9M, resulting in an operating profit margin of -113.7%. This margin reflects the operational efficiency of the business before interest and taxes.
UroGen Pharma Ltd. (URGN) generated $97.3M in gross profit for the year, representing a gross profit margin of 88.7%. This demonstrates the company's core pricing power and production efficiency.